对阿尔茨海默病的运动改善:突出FGF21诱导的大脑血管保护
Juan Wang1, Xiangyuan Meng1, Jialun Yang1
1Hunan Provincial Key Laboratory of Physical Fitness and Sports Rehabilitation, Hunan Normal University, No. 437, Lushan South Road, Changsha, Hunan Province, 410012, China.
Neurochemical research
|February 4, 2025
概括
纤维细胞生长因子21 (FGF21) 通过保护大脑血管,在治疗阿尔茨海默病 (AD) 方面表现有前途. 运动促进FGF21,为AD预防和治疗提供了一条新的途径.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,患病率不断增加,对社会产生重大影响.
- 早期的血管损伤和通过血脑屏障的粉样β (Aβ) 运输受损在AD病变发生过程中至关重要.
- 纤维细胞生长因子21 (FGF21),是新陈代谢的内分泌调节剂,具有与大脑受体的抗衰老和血管保护性质.
研究的目的:
- 审查FGF21.2的生物特征.
- 检查FGF21在与阿尔茨海默氏症相关的大脑血管功能障碍中的作用.
- 探索运动影响FGF21的机制,以防止AD引起的血管变化.
主要方法:
- 对FGF21的生物特性进行文献综述.
- 在大脑血管健康和AD的背景下对FGF21的研究分析.
- 研究运动诱导的FGF21产生及其神经血管效应.
主要成果:
- FGF21表现出显著的血管保护作用,并与代谢调节有关.
- 在AD中的Aβ沉积会对脑血管结构和功能产生负面影响.
- 运动刺激FGF21的释放,通过血脑屏障促进神经血管的保护.
结论:
- FGF21代表了缓解AD相关的脑血管损伤的潜在治疗标.
- 运动介导的FGF21增加为管理阿尔茨海默病提供了一个有前途的非药物治疗策略.
- 了解FGF21在运动中的机制为开发对神经退行性疾病的干预提供了新的基础.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
10:36In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
8.4K
相关概念视频
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
